Rhumbline Advisers Viracta Therapeutics, Inc. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.87 - $5.0 $72,355 - $193,465	-38,693 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.23 - $4.76 $7,798 - $16,645	3,497 Added 9.94%	38,693 $184,000
Q4 2021 Feb 10, 2022	SELL	$3.37 - $7.91 $2,628 - $6,169	-780 Reduced 2.17%	35,196 $128,000
Q3 2021 Nov 12, 2021	BUY	$7.84 - $12.53 $46,208 - $73,851	5,894 Added 19.59%	35,976 $289,000
Q2 2021 Aug 05, 2021	BUY	$7.55 - $12.95 $227,119 - $389,561	30,082 New	30,082 $341,000

9.39M

5.9K

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $18.4M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.